Pfizer on OTC sale
This article was originally published in The Tan Sheet
Executive Summary
Bids for Pfizer's OTC division during a June 6 auction reportedly topped $15 bil., while bidders included GlaxoSmithKline, Johnson & Johnson and Reckett Benckiser. Pfizer says it is still maintaining the option of spinning the division off to shareholders 1("The Tan Sheet" May 29, 2006 p. 6 ). "The review is continuing, and we will be announcing which of the strategic options [we choose] in the third quarter," a Pfizer spokesman said...
You may also be interested in...
Pfizer Weighs Options For OTC Division As Investors Line Up For Purchase
While Pfizer considers whether to sell its Consumer Healthcare unit or spin it off to shareholders, potential buyers are placing bids with an eye toward an early June deadline
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.